MNPR heads into tomorrow's August 14 print with analyst conviction building and a short position that has shed nearly 40% of its mass in a month — yet enough residual bears remain to make this a genuine binary event.
The analyst backdrop has turned more constructive than at any point this year. BTIG raised its price target to $133 yesterday — the day before earnings — maintaining its Buy rating and lifting from $117. That follows HC Wainwright's move to $125 in late July, up from $105. The consensus mean target now sits at around $123, modestly above the current $114.90 price. All eight covering analysts rate the stock a Buy. The bull case centres on ALXN1840's rolling NDA submission for Wilson disease, a well-characterised safety profile, and differentiation from existing chelation approaches. Bears point to the standard pre-commercial risks: clinical, regulatory, and financial hurdles that remain real for a company yet to put a product on the market.
The short-covering story reported here two days ago has continued without reversal. Short interest remains at roughly 14.5% of free float — down from above 23% a month ago and over 38% of the peak short position returned — but the residual position is still meaningful. The short score at 70.9 places MNPR in the upper tier of the universe on short pressure, even after the sustained unwind. Borrow availability has opened to 114%, meaning roughly 1.4 shares are available to lend for every share currently borrowed. That is a dramatic loosening from mid-July, when availability was as tight as 18%. Cost to borrow has also eased, running near 1.9% — about half its July peak — consistent with a market where shorts are no longer fighting for access to stock.
Among correlated peers, price action over the past week has been mixed. RYTM and NRIX gained around 7% and 5% respectively, while FDMT and SLN rallied harder. That relative firmness in the peer group provides a mildly supportive backdrop, though MNPR's correlation to any single peer tops out near 48%, limiting how much read-across applies. The stock itself is up roughly 8% over the past month and off 3.6% on the week, a pattern consistent with profit-taking ahead of a known catalyst.
Tomorrow's print is less a test of whether the NDA process is on track and more a test of whether the company's cash runway and clinical update justify the target-price upgrades the Street has been layering on throughout the summer.
See the live data behind this article on ORTEX.
Open MNPR on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
